{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-037255","form_type":"8-K","ticker":"FENC","cik":"0001211583","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.593768+00:00","generated_at":"2026-06-04T09:35:20.274632+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Fennec licenses PEDMARQSI to Norgine for EU/AU/NZ; €40M upfront, up to €210M milestones","bullets":["Exclusive license covers Europe (incl. UK), Australia, New Zealand; Norgine to commercialize.","Fennec receives €40M upfront paid March 15, 2024, plus up to €210M in regulatory/commercial milestones.","Tiered royalties on net sales range from mid-teens to mid-twenties percent.","PEDMARQSI is first EU/U.K.-approved therapy to reduce cisplatin-induced hearing loss in pediatric patients.","Estimated >5,000 pediatric patients/year eligible in Europe; approvals based on Phase 3 trials showing ~50% hearing loss reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-037255","json":"https://secwatch.observer/filing/0001104659-24-037255.json","markdown":"https://secwatch.observer/filing/0001104659-24-037255.md","text":"https://secwatch.observer/filing/0001104659-24-037255.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924037255/0001104659-24-037255-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924037255/tm249428d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:35:20.274632+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b0abdb9352456a6e93bac07f4b9bb820ea6f7ccb","claim":"FENNEC PHARMACEUTICALS INC. entered into License and Supply Agreement with Norgine Pharma UK Limited valued at €40 million (effective 2024-03-15).","evidence_excerpt":"On March 15, 2024, Fennec Pharmaceuticals, Inc., a Delaware corporation (“Fennec”) and wholly owned subsidiary of Fennec Pharmaceuticals Inc. (the “Company”), entered into a License and Supply Agreement (the “Agreement”) with Norgine Pharma UK Limited (“Norgine”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924037255/0001104659-24-037255-index.htm","confidence":1.0,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Norgine Pharma UK Limited"},{"label":"Value","value":"€40 million"},{"label":"Effective","value":"2024-03-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}